Irritable bowel syndrome (IBS) is a part of the larger group of functional gastrointestinal disorders (FGIDs), which have different bodily locations and symptom patterns, but which share disturbances in the regulation of peripheral, spinal and central pathways that are incompletely understood.¹ IBS patients suffer from a chronic gastrointestinal (GI) disorder characterized by recurrent abdominal pain associated with altered bowel habits without obvious structural abnormalities seen on endoscopy or X-ray.^2,3 The prevalence is high, affecting up to 20% of adults.⁴ When moderate to severe in intensity, patients struggle with severe pain or discomfort, abnormal bowel habit, impaired health-related quality of life (HRQOL) and disability.⁵ This can lead to high work absenteeism, physician visits and health care costs.^6,7

Although highly prevalent in society, patients with IBS may not always receive optimal treatment. Physicians, including gastroenterologists, may feel unsure as to how to manage conditions without clear structural findings, since this is how traditionally physicians are trained. They may perceive this as "illness" without "disease." Furthermore, they may not fully understand the multiplicity of factors operative in understanding the pathophysiology which adheres to a brain-gut biopsychosocial model. As such, this disorder can be associated with major psychosocial distress that some physicians may feel ill equipped to manage. Early life experiences including major loss abuse and psychosocial trauma, family influences on illness behavior and maladaptive coping life-styles can influence the clinical expression and severity of IBS. These factors also produce complex interactions that affect biological, psychological and social systems for the individual with IBS. Thus abdominal symptoms as presented by IBS patients are only a part of the full understanding of full syndrome, perhaps an "alarm sign" of a complex of biopsychosocial factors.

In recent years scientific investigations have brought a greater understanding of the pathophysiological processes leading to the symptom complex of IBS and in the process have made these disorders clinically legitimate. The data have also led to improved clinical care and increased public awareness. This report provides a better understanding of these newly understood biopsychosocial determinants as part of an up-to-date synthesis of current research (Table 1).

More recent scientific studies link the mind and the body as a part of a system where their dysregulation can produce illness. The term "bio-psycho-social" does not mean merely that psychosocial issues are important, or that psychosocial factors cause medical illness (psychogenic and psychosomatic), or that psychological symptoms result from a medical disorder (somatopsychic or psychologic overlay), or even that stress has physiologic effects (psychophysiologic), although all may be considered as plausible situations subsumed by the model.^8-10

The biopsychosocial model of illness and disease, as described by Engel,^8,10,11 has helped understanding the bi-directional relationship between mind and body and reconcileed the dualistic concepts that separated illness and disease. Figure illustrates this biopsychosocial understanding of the relationship between psychosocial and physiological factors associated with functional GI symptoms and the clinical outcome.¹²

Early Life

The natural history of symptoms and risk factors that contribute to IBS may begin in early life. Familial studies of IBS have demonstrated that reporting a first-degree relative with abdominal pain or bowel problems is significantly associated with reporting of IBS symptoms,¹³ suggesting a strong environmental basis for IBS. Heredity may explain the findings that IBS tends to run in families. Both the Australian twins study¹⁴ and the larger US study¹⁵ showed concordance rate for IBS between monozygotic twins was significantly higher than that between dizygotic twins. Genetic factors which may be associated with FGIDs may include serotonin transporter,¹⁶ IL-10¹⁷ and other genetic polymorphisms. Parental attitudes may also be important to the development or clinical expression of IBS. Levy et al^15,18 indicated that children of patients with IBS had significantly more health care visits than those without IBS.^19,20 Children whose mothers have IBS are prone to having more non-GI symptoms as well as GI symptoms. This may imply that parents tend to pay attention to trivial symptoms, sometimes referred to as "illness behavior".²¹ Trained parents who do not pay attention to their children's complaints produce fewer chronic functional abdominal symptoms than the parents who do show attention.²² Thus both a genetic and a social learning may contribute to the intergenerational transmission of IBS.

Psychosocial Factors

Physiology

Outcome

IBS status shows an aspect of illness. "Illness" is defined as the personal experience of the medical condition, which is evident from the person's symptom reports, perceptions, and behavior. "Disease" is abnormalities in the structure and function of organs and tissues. It is externally verifiable by evidence from a pathological state. Illness can be inappropriately dichotomized to a disease, or organic disorder, which presumably distinguish medical (organic) from psychological (functional) illness or relegates functional illness to a condition with no cause or treatment.⁸

Appropriate coping and social supports may manage the effects of life stress, abuse, and morbid psychological factors on the illness and its outcome. Coping has been defined as "problem solving efforts, both action-oriented and intrapsychic, to manage external and internal demands and conflicts that are apprised as taxing or exceeding a person's resources".⁶⁷ In general, emotion-focused coping, although possibly adaptive for acute overwhelming stresses, is not effective for chronic stressors. Whereas problem-focused coping strategies (eg, seeking social support or reappraising the stressor) involves efforts by finding out one's response to the stressor and learning skills to manage the problems, that is more effective for chronic illness. Social supports through family, supportive relationships, social participation and social networks can have similar benefits in reducing the impact of stressors on physical and mental illness, thereby improving ability to cope with the illness.⁶⁸ Therefore, IBS patients, who have severe and chronic life threats, may lack of satisfactory interpersonal support. They also cannot improve the symptom intensity over time and reduce the HRQOL.^28,69

To control IBS symptoms, some medications based on the pathophysiology are often used. Motility and pain modifying medications, such as enteric agents, fiber, prokinetics, are useful, in particular, for mild IBS.⁷⁰ However, physicians may treat patients with more severe symptoms whose medications are not working as well as hoped. Because psychological factors often adversely affect IBS, psychopharmacological or psychological treatments can be employed to reduce their impact on the GI symptoms. Furthermore, good psychosocial treatment must also rest on good relationships between physician and patients - the patient-physician relationship.

Approach to the Patient

In the course of caring and evaluating for patients, different perspectives between patients and physicians may occur with regard to the role of psychosocial factors in the illness. Certainly psychosocial factors may influence symptoms and behaviors in ways that are not readily treatable by disease-specific methods.⁸ Some patients, for example those who have experienced severe traumatic events such as sexual abuse, may initially be unwilling to accept the role of psychosocial factors in the illness. It is important for the physician to develop an effective patient-physician interaction, to improve the therapeutic outcome. This can be established with attention to several issues: (1) make an effort to understand and offer empathy when patients report the experience of the illness; (2) obtain the history and acknowledge the role of the patient's psychological factors; (3) clarify any misunderstandings; (4) provide education how to manage the illness, including psychosocial function; and (5) make a plan of treatment with the patient.^29,71

Physicians should also obtain histories about the associations between bowel symptoms and psychosocial factors. Obtaining information that relates the daily pattern of the symptoms to aggravating factors such as the timing of menstruation, dietary or life-style changes and stressors can provide the basis for behavioral modification or even cognitive-behavioral strategies. Thus, the therapeutic plan should be individualized and established on the relationships between the patient and physician.

It is preferable for gastroenterologists and primary care doctors to work closely with mental health professional, if available. In particular, this should occur if the patient shows (1) a severe depression, which may be accompanied by suicidal ideas, (2) chronic refractory pain, (3) severe disability, (4) maladaptive illness behavior, (5) difficulties in physician-patient interaction, (6) idiosyncratic health beliefs and (7) other identifiable psychiatric difficulties (somatization disorder, post-traumatic stress disorder and severe anxiety), history of abuse that leads to continuing distress and/or marked distress (Table 2).^28,72

Psychopharmacology

Psychopharmacologic agents work on neurotransmitter receptors in the brain-gut regulatory pathways that target serotonergic, dopaminergic, opioidergic and noradrenergic receptor sites in the brain. Their effects may be to reduce central modulation of visceral afferents, moderate visceral pain, and improve underlying psychiatric conditions, such as anxiety, depression, nausea, and loss of appetite.⁷⁰ Prescribing psychopharmacologic agents is best accomplished in the context of a strong physician-patient relationship, where these agents are complementary to an overall multicomponent treatment plan. The physician is required to explain the possible side effects, and expected benefits from the medication and address to ensure consistent treatment at an appropriate dose level over a longer period of time (2-3 months) than change rapidly from one drug to another. The tricyclic antidepressants (TCAs), which block transporters of norepinephrine and serotonin, in relatively low doses can reduce chronic pain.⁷³ Selective serotonin reuptake inhibitors (SSRI) are used to reduce anxiety and are particularly helpful for psychiatric comorbid conditions, including major depression, panic disorder and other high-anxiety conditions.⁷⁴ However, SSRIs have little antinociceptive agents and their prokinetic effect which produce cramping, nausea and diarrhea, the patient with abdominal pain, diarrhea or nausea would do well with a TCA. The serotonin-norepinephrine reuptake inhibitors and the noradrenergic and specific serotonergic antidepressant are relatively new classes of antidepressants that have substantial serotonergic and noradrenergic effects (unlike the SSRIs) to be particularly helpful for the treatment of painful conditions, but without the antihistaminic and anticholinergic effects of the TCAs that lead to most of the side effects, including dry mouth, difficulty urinating, constipation, decrease in sexual ability, nausea, increased heart rhythms, migraine, appetite change, and weight gain.^72,75-77

Anxiolytic agents, particularly the benzodiazepines, are effective for reducing anxiety in the short term, particularly if the anxiety is associated with stress induced flare-ups of bowel disturbance.⁷⁰ With considering the long-term basis of CNS depressant effect, the potential benefit should be balanced with the long-term risks of sedation, drug interactions, habituation and rebound after withdrawal.

In order to avoid side effects of these drugs, psychopharmacologic medication would be started with low doses and then gradually increased. Some side effects often go away after the first few weeks of drug medication. Medication should be stopped with intolerable side effects. Other strategies may exist to manage psychopharmacologic-induced dysfunction, including waiting, reducing, use of adjunctive pharmacotherapy, and switching to another drugs.

Opiates have little role in treating patients with chronic pain or psychosocial disturbance and often induce narcotic bowel syndrome. A narcotic help the pain at first, but the progressive and paradoxical increase in abdominal pain is followed despite continued or escalated dosages of narcotic prescribed in an effort to relieve the pain.^30,78 It can be seen in the patient who often visits emergency department or the clinical service with no diagnosis or meaningful treatment plan and is prescribed with opiates.⁷¹

The placebo response rate in IBS trials is high, which is approximately 47%,⁷⁹ and providing placebo treatment with defined positive physician-patient relationships showed higher clinical outcome.⁸⁰ An effective physician-patient relationship would help to manage a consistent plan of narcotic withdrawal coupled with the initiation of effective alternative treatments to manage the pain and bowel symptoms.

Psychotherapies

Psychological treatments (eg, cognitive behavioral therapy, dynamic psychotherapy and hypnotherapy) are often appropriate for IBS patients.⁸¹ Cognitive behavioral therapy helps IBS patients to learn new ways of thinking and behaving skills for taking a more proactive role in controlling symptoms, coping with their emotional anxieties, and improving illness beliefs in chronic pain.^82,83 Dynamic psychotherapy consists of close relationships between the patient and therapist, which induce the patient to overcome internal resistance and learn how to respond in such relationship.⁸³ Hypnotherapy, which alters the conscious state, requires specialized training to be used in IBS.^57,84 Psychological treatments are, as a class of interventions, effective in reducing symptoms compared with a pooled group of control conditions.⁸⁵ The most important aspect of treatment is the patient's acceptance of the need for treatment and his or her motivation to engage in it. This can be indicated if the gastroenterologist and psychologist/psychiatrist help the patient to accept the treatment as a necessary part of an overall plan of care.

IBS is often explained as a "functional" disorder, meaning the inclusion of both physiological and psychological factors. When an IBS patient is first seen, he or she often mainly complains about chronic abdominal symptoms, such as pain, discomfort, and diarrhea. While some physicians may focus primarily on "abdominal" symptoms, from the point of view of biopsychosocial model, stress can play an important part in the full clinical expression and outcome of the disorder. Therefore, physicians should focus on integrating the medical components of the illness with the patient's psychological aspects and try to build a more satisfactory treatment on this understanding.

Using the concept of biopsychosocial model may be a good way to explain the interaction between psychological and physiological factors, which may exist in patients with IBS. However, research methods of brain and gut, or stress and cognition are limited, thus further studies are awaited.